Terms: = Ovarian cancer AND uPA AND Treatment
50 results:
1. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.
Nair HB; Santhamma B; Dileep KV; Binkley P; Acosta K; Zhang KYJ; Schenken R; Nickisch K
Sci Rep; 2019 Nov; 9(1):17279. PubMed ID: 31754172
[TBL] [Abstract] [Full Text] [Related]
2. Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic upa-derived peptide: first in vitro evaluations.
Wacker A; Bauder-Wüst U; Schäfer M; Schmidt J; Remde Y; Stadlbauer S; Eder M; Liolios C; Kopka K
J Labelled Comp Radiopharm; 2019 Jun; 62(8):483-494. PubMed ID: 30970388
[TBL] [Abstract] [Full Text] [Related]
3. Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.
Momeny M; Sabourinejad Z; Zarrinrad G; Moghaddaskho F; Eyvani H; Yousefi H; Mirshahvaladi S; Poursani EM; Barghi F; Poursheikhani A; Dardaei L; Bashash D; Ghazi-Khansari M; Tavangar SM; Dehpour AR; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Sci Rep; 2017 Apr; 7():45954. PubMed ID: 28383032
[TBL] [Abstract] [Full Text] [Related]
4. RhoA/ROCK pathway mediates leptin-induced upa expression to promote cell invasion in ovarian cancer cells.
Ghasemi A; Hashemy SI; Aghaei M; Panjehpour M
Cell Signal; 2017 Apr; 32():104-114. PubMed ID: 28104444
[TBL] [Abstract] [Full Text] [Related]
5. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract] [Full Text] [Related]
6. Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
Communal L; Vilasco M; Hugon-Rodin J; Courtin A; Mourra N; Lahlou N; Le Guillou M; Perrault de Jotemps M; Chauvet MP; Chaouat M; Pujol P; Feunteun J; Delaloge S; Forgez P; Gompel A
Oncotarget; 2016 Jul; 7(29):45317-45330. PubMed ID: 27246982
[TBL] [Abstract] [Full Text] [Related]
7. A novel upag-KPI fusion protein inhibits the growth and invasion of human ovarian cancer cells in vitro.
Zhao LP; Xu TM; Kan MJ; Xiao YC; Cui MH
Int J Mol Med; 2016 May; 37(5):1310-6. PubMed ID: 27035617
[TBL] [Abstract] [Full Text] [Related]
8. Biomarkers in Breast cancer: Where Are We and Where Are We Going?
Duffy MJ; Walsh S; McDermott EW; Crown J
Adv Clin Chem; 2015; 71():1-23. PubMed ID: 26411409
[TBL] [Abstract] [Full Text] [Related]
9. Expression and activity analysis of a new fusion protein targeting ovarian cancer cells.
Su M; Chang W; Wang D; Cui M; Lin Y; Wu S; Xu T
Oncol Rep; 2015 Sep; 34(3):1337-44. PubMed ID: 26166362
[TBL] [Abstract] [Full Text] [Related]
10. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
Mashiko S; Kitatani K; Toyoshima M; Ichimura A; Dan T; Usui T; Ishibashi M; Shigeta S; Nagase S; Miyata T; Yaegashi N
Cancer Biol Ther; 2015; 16(2):253-60. PubMed ID: 25587663
[TBL] [Abstract] [Full Text] [Related]
11. Expression and anticancer activity analysis of recombinant human upa1‑43-melittin.
Su M; Chang W; Cui M; Lin Y; Wu S; Xu T
Int J Oncol; 2015 Feb; 46(2):619-26. PubMed ID: 25394558
[TBL] [Abstract] [Full Text] [Related]
12. Application of ulipristal acetate in female patients with uterine fibroids.
Grzechocinska B; Gadomska H; Zygula A; Wielgos M
Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
[TBL] [Abstract] [Full Text] [Related]
13. Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by αvβ6 integrin-mediated signaling in ovarian cancer.
Xue B; Wu W; Huang K; Xie T; Xu X; Zhang H; Qi C; Ge J; Yu Y
Mol Cell Biochem; 2013 Aug; 380(1-2):177-84. PubMed ID: 23615713
[TBL] [Abstract] [Full Text] [Related]
14. Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.
Dong Y; Stephens C; Walpole C; Swedberg JE; Boyle GM; Parsons PG; McGuckin MA; Harris JM; Clements JA
PLoS One; 2013; 8(2):e57056. PubMed ID: 23451143
[TBL] [Abstract] [Full Text] [Related]
15. Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines.
Roomi MW; Kalinovsky T; Rath M; Niedzwiecki A
Oncol Rep; 2012 Sep; 28(3):768-76. PubMed ID: 22736175
[TBL] [Abstract] [Full Text] [Related]
16. Differential expressions of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion.
Kwon Y; Cukierman E; Godwin AK
PLoS One; 2011 Apr; 6(4):e18872. PubMed ID: 21526198
[TBL] [Abstract] [Full Text] [Related]
17. Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion.
Miyanishi N; Suzuki Y; Simizu S; Kuwabara Y; Banno K; Umezawa K
Biochem Biophys Res Commun; 2010 Dec; 403(1):154-9. PubMed ID: 21059341
[TBL] [Abstract] [Full Text] [Related]
18. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
Konecny GE; Glas R; Dering J; Manivong K; Qi J; Finn RS; Yang GR; Hong KL; Ginther C; Winterhoff B; Gao G; Brugge J; Slamon DJ
Br J Cancer; 2009 Nov; 101(10):1699-708. PubMed ID: 19861960
[TBL] [Abstract] [Full Text] [Related]
19. Coexpression of invasive markers (upa, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.
Chen H; Hao J; Wang L; Li Y
Br J Cancer; 2009 Aug; 101(3):432-40. PubMed ID: 19603017
[TBL] [Abstract] [Full Text] [Related]
20. S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac.
Devine KM; Smicun Y; Hope JM; Fishman DA
Gynecol Oncol; 2008 Aug; 110(2):237-45. PubMed ID: 18513786
[TBL] [Abstract] [Full Text] [Related]
[Next]